scholarly journals Diabetes Mellitus and Autoimmune Hepatitis: Demographical and Clinical Description of a Relatively Rare Phenotype

2018 ◽  
Vol 50 (07) ◽  
pp. 568-574
Author(s):  
Gideon de Sousa ◽  
Nicole Prinz ◽  
Marianne Becker ◽  
Renate Dürr ◽  
Uta Faller ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Liver Enzymes ◽  
Lower Percentage ◽  
Oral Antidiabetic Drugs ◽  
Autoimmune Thyroid ◽  
Antidiabetic Therapy ◽  
Patients With Diabetes ◽  
Rare Phenotype ◽  
Clinical Description ◽  
Diabetes Patients

AbstractWe studied demographic, metabolic, and clinical characteristics of patients with diabetes and autoimmune hepatitis (AIH) from the German/Austrian DPV registry. A total of 139 patients with diabetes and AIH were analyzed and compared to 437 728 patients with diabetes without AIH. The prevalence of AIH in patients with T1DM (44.8/100 000) seems higher than in the general population, the prevalence of AIH in patients with T2DM (23.6/100 000) does not seem to be increased. Patients with T2DM and AIH had a shorter duration of diabetes (p=0.007) and a higher proportion of females (p<0.001) compared to T2DM without AIH. Patients with diabetes (T1DM or T2DM) and AIH required higher insulin doses (p<0.001 and p=0.03, respectively) and showed increased liver enzymes (aspartate transaminase, alanine transaminase, gamma-glutamyltransferase) compared to diabetes patients without (all p<0.001). We detected a lower percentage of patients treated with oral antidiabetic drugs (p=0.01) and a higher percentage of patients treated by insulin in patients with T2DM and AIH (p<0.001) compared to patients with T2DM alone. We observed a higher incidence of autoimmune thyroid disease (AIT) in patients with diabetes (T1DM or T2DM) and AIH (p<0.001) compared to diabetes patients without AIH. AIH seems more frequent in patients with T1DM. Patients with diabetes and AIH require intensification of antidiabetic therapy and seem to have a higher prevalence of AIT.

scholarly journals The Association of Coagulation Indicators and Coagulant Agents With 30-Day Mortality of Critical Diabetics

2021 ◽  
Vol 27 ◽  
pp. 107602962110263
Author(s):  
Yingxin Huang ◽  
Zhihua Zhong ◽  
Fanna Liu
Keyword(s):  
Subgroup Analysis ◽  
Medical Information ◽  
Cardiovascular Effects ◽  
World Health ◽  
Coagulation System ◽  
Hospital Death ◽  
Hazard Regression ◽  
Risk Of Mortality ◽  
Patients With Diabetes ◽  
Diabetes Patients

Diabetes, regarded as a global health concerned disease, was focused by the World Health Organization (WHO). Patients with diabetes may have a hypercoagulable and hypo-fibrinolysis state. There is lots of research about cardiovascular effects on diabetes patients, but less about the coagulation system. This study is designed to investigate the relationship between coagulation indicators and 30-day mortality of critical diabetes patients. In this retrospective, single-center study, we included adult patients diagnosed with diabetes. Data, including demographic, complication, laboratory tests, scoring system, and anticoagulant treatment, were extracted from Medical Information Mart for Intensive Care (MIMIC-III). The receiver operating characteristic (ROC) curve and Kaplan-Meier curve were applied to predict the association of mortality and coagulation indicators. Cox hazard regression model and subgroup analysis were used to analyze the risk factors associated with 30-day mortality. A total of 4026 patients with diabetes mellitus were included in our study, of whom 3312 survived after admitted to the hospital and 714 died. Cox hazard regression showed anticoagulant therapy might decrease the risk of 30-day mortality after adjusted. In age <70 subgroup analysis, we found that patients with PTT <26.8 s or lightly increased PT may increase odds of 30-day hospital death (HR, 95%CI, 2.044 (1.376, 3.034), 1.562 (1.042, 2.343)). When age >70, lightly increased PTT may reduce the risk of mortality, but PT >16.3 s, a high level of hypo-coagulation state, increase risk of mortality (HR, 95%CI, 0.756 (0.574, 0.996), 1.756 (1.129, 2.729)). Critical diabetes patients may benefit from anticoagulant agents. The abnormal coagulant function is related to the risk of 30-day mortality.

scholarly journals Ten-year cardiovascular risk in diabetes patients without of coronary artery disease – a Danish cohort study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
K.K.W Olesen ◽  
M Madsen ◽  
C Gyldenkerne ◽  
P.G Thrane ◽  
T Thim ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery Disease ◽  
Ischemic Stroke ◽  
Cardiovascular Risk ◽  
General Population ◽  
Funding Source ◽  
Increased Risk ◽  
Patients With Diabetes ◽  
Artery Disease ◽  
Diabetes Patients

Abstract Background Patients with diabetes without obstructive coronary artery disease (CAD) by coronary angiography (CAG) have a risk of myocardial infarction (MI) similar to that of non-diabetes patients without CAD. Their cardiovascular risk compared to the general population is unknown. Purpose We examined the 10-year risks of myocardial infarction (MI), ischemic stroke, and death in diabetes patients without CAD after CAG compared to the general population. Methods We included all diabetes patients without obstructive CAD examined by CAG from 2003–2016 in Western Denmark and an age and sex matched comparison group, sampled from the general population in Western Denmark without previous history of coronary heart disease. Outcomes were MI, ischemic stroke, and death. The 10-year cumulative incidences were estimated. Adjusted hazard ratios (HRs) were estimated by stratified Cox regression using the general population as the reference group. Results We identified 5,760 diabetes patients without obstructive CAD and 29,139 individuals from the general population. Median follow-up was 7 years with 25% of participants followed for up to 10 years. Diabetes patients without obstructive CAD had an almost similar 10-year risk of MI (3.2% vs 2.9%, adjusted HR 0.91, 95% CI 0.70–1.17, Figure) compared to the general population cohort. Diabetes patients had an increased risk of ischemic stroke (5.2% vs 2.2%, adjusted HR 1.88, 95% CI 1.48–2.39), and death (29.7% vs 17.9%, adjusted HR 1.41, 95% CI 1.29–1.54). The duration of diabetes was associated with increased cardiovascular risk. Conclusions Absence of obstructive CAD by CAG in patients with diabetes ensures a low MI risk similar to the general population, but diabetes patients still have an increased risk of ischemic stroke and all-cause death despite absence of CAD. Figure 1 Funding Acknowledgement Type of funding source: Public hospital(s). Main funding source(s): Department of Cardiology, Aarhus University Hospital

scholarly journals Depression among patients with diabetes mellitus in a Nigerian teaching hospital

2010 ◽  
Vol 16 (2) ◽  
pp. 4 ◽  
Author(s):  
Bawo Onesirosan James ◽  
Joyce Ohiole Omoaregba ◽  
George Eze ◽  
Olufemi Morakinyo
Keyword(s):  
Diabetes Mellitus ◽  
Control Group ◽  
Depression Symptoms ◽  
Depression Symptom ◽  
Treatment Goals ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Prevalence Of Depression ◽  
Patients With Diabetes ◽  
Diabetes Patients

<p><strong>Objectives.</strong> Depression is associated with diabetes mellitus and affects treatment goals negatively. We aimed to determine the prevalence of depression and identify its socio-demographic or clinical correlates among patients with diabetes mellitus attending an out-patient clinic in Nigeria.</p><p><strong>Methods.</strong> Two hundred consecutively recruited diabetes patients (index group) were compared with a similar number of apparently healthy controls in a cross-sectional survey. In both groups, in addition to obtaining socio-demographic details, depression was diagnosed using the Schedule for the Clinical Assessment in Neuropsychiatry (SCAN), while the Beck Depression Inventory (BDI) was used to assess depression symptom severity. <strong></strong></p><p><strong>Results.</strong> Sixty (30%) diabetes patients met a SCAN diagnosis for clinical depression, compared with 19 (9.5%) in the control group. Having a smaller income and more children were significantly correlated with higher depression symptoms on the BDI.</p><p><strong>Conclusion.</strong> Depression is highly co-morbid with diabetes mellitus. The care of individuals with diabetes mellitus should include the screening and possible treatment for depression in order to achieve and sustain treatment goals.</p>

scholarly journals Depression and Anxiety among Patients with Type II Diabetes Mellitus in Chitwan Medical College Teaching Hospital, Nepal

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Kalpana Sharma ◽  
Govinda Dhungana ◽  
Shailendra Adhikari ◽  
Archana Bista Pandey ◽  
Muna Sharma
Keyword(s):  
Diabetes Mellitus ◽  
College Teaching ◽  
Educational Status ◽  
Current Treatment ◽  
Depression And Anxiety ◽  
Medical College ◽  
Prevalence Of Depression ◽  
Patients With Diabetes ◽  
History Of ◽  
Diabetes Patients

The prevalence of depression and anxiety disorders is common among people with diabetes mellitus. Coexistence of diabetes and depression/anxiety increases the risk of diabetes complications and reduces the overall quality of life. Hence, this study aimed to assess the depression and anxiety among patients with type 2 diabetes mellitus in Chitwan. Descriptive survey was carried out among 296 purposively selected clinically diagnosed type 2 diabetes patients admitted in the Chitwan Medical College Teaching Hospital from 15th June 2018 to 17th September 2019. Patients were interviewed using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorders-7 (GAD-7). Data were analyzed using descriptive and inferential statistics. Of 296 diabetic patients, 48.6% were 60 years and above, 59.5% female and 61.5% literate; their common occupation was agriculture (38.2%) followed by household work (26.4%). Nearly two-thirds (62.8%) of diabetes patients had other chronic comorbid conditions. Depression and anxiety were observed among 57.8% and 49.7% of diabetes patients, respectively. While observing the severity, 27.4%, 19.6%, 8.4%, and 2.4% of patients had mild, moderate, moderately severe, and severe depression, respectively. Likewise, 24.7%, 20.3%, and 4.7% of patients had mild, moderate, and severe anxiety, respectively. Current living status, educational status, medicine adherence, satisfaction toward current treatment, and history of mental illness in the family were found to be significant factors associated with the anxiety of patients with diabetes. Further, educational status, smoking habit, satisfaction towards current treatment, and history of diabetes in family were the factors associated with depression. Prevalence of depression and anxiety is high among admitted patients with diabetes mellitus, and many factors are associated with it. Hence, regular screening services are essential along with diabetes management plan for timely identification and treatment of the vulnerable groups in the healthcare centers.

scholarly journals Metformin Use Is Associated with Decreased Mortality in COVID-19 Patients with Diabetes: Evidence from Retrospective Studies and Biological Mechanism

2021 ◽  
Vol 10 (16) ◽  
pp. 3507
Author(s):  
Tahmina Nasrin Poly ◽  
Md. Mohaimenul Islam ◽  
Yu-Chuan (Jack) Li ◽  
Ming Chin Lin ◽  
Min-Huei Hsu ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Endothelial Damage ◽  
Lung Damage ◽  
Vascular Endothelial ◽  
Online Databases ◽  
Risk Of Mortality ◽  
Patients With Diabetes ◽  
Risk Ratios ◽  
Diabetes Patients

Background and Aims: The coronavirus disease 2019 (COVID-19) increases hyperinflammatory state, leading to acute lung damage, hyperglycemia, vascular endothelial damage, and a higher mortality rate. Metformin is a first-line treatment for type 2 diabetes and is known to have anti-inflammatory and immunosuppressive effects. Previous studies have shown that metformin use is associated with decreased risk of mortality among patients with COVID-19; however, the results are still inconclusive. This study investigated the association between metformin and the risk of mortality among diabetes patients with COVID-19. Methods: Data were collected from online databases such as PubMed, EMBASE, Scopus, and Web of Science, and reference from the most relevant articles. The search and collection of relevant articles was carried out between 1 February 2020, and 20 June 2021. Two independent reviewers extracted information from selected studies. The random-effects model was used to estimate risk ratios (RRs), with a 95% confidence interval. Results: A total of 16 studies met all inclusion criteria. Diabetes patients given metformin had a significantly reduced risk of mortality ((RR 0.65; 95% CI: 0.54–0.80, p < 0.001, heterogeneity I2 = 75.88, Q = 62.20, and τ2 = 0.06, p < 0.001)) compared with those who were not given metformin. Subgroup analyses showed that the beneficial effect of metformin was higher in the patients from North America (RR 0.43; 95% CI: 0.26–0.72, p = 0.001, heterogeneity I2 = 85.57, Q = 34.65, τ2 = 0.31) than in patients from Europe (RR 0.67; 95% CI: 0.47–0.94, p = 0.02, heterogeneity I2 = 82.69, Q = 23.11, τ2 = 0.10) and Asia (RR 0.90; 95% CI: 0.43–1.86, p = 0.78, heterogeneity I2 = 64.12, Q = 11.15, τ2 = 0.40). Conclusion: This meta-analysis shows evidence that supports the theory that the use of metformin is associated with a decreased risk of mortality among diabetes patients with COVID-19. Randomized control trials with a higher number of participants are warranted to assess the effectiveness of metformin for reducing the mortality of COVID-19 patients.

Evaluate the Impact of Diabetes on RA-related outcomes in an Electronic Health Record-Based Rheumatology Registry

2020 ◽  
pp. jrheum.200486
Author(s):  
Huifeng Yun ◽  
Fenglong Xie ◽  
Lang Chen ◽  
Shuo Yang ◽  
Leticia Ferri ◽  
...  
Keyword(s):  
Linear Models ◽  
Cox Regression ◽  
Health Assessment ◽  
Diabetic Patients ◽  
Informatics System ◽  
Diagnosis Codes ◽  
Hazard Ratios ◽  
Patients With Diabetes ◽  
The Impact ◽  
Diabetes Patients

Objective RA patients with diabetes might have worse clinical outcomes and adverse events compared to non-diabetes patients. We evaluated the effects of diabetes on HAQ (Health Assessment Questionnaire) change and outpatient infection in RA patients. Methods Using the ACR’s Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry, we identified RA patients who had ≥1 rheumatologist visit with a HAQ measured (index visit) in 2016, ≥1 previous visit, and a subsequent outcome visit with same HAQ measured at 12 months (± 3 months). We identified diabetes by diagnosis codes, medications, or lab values. Outpatient infection was defined by diagnosis codes or anti-infective medications. We calculated mean HAQ change and incidence rate (IR) of outpatient infections among patients with and without diabetes. Generalized linear models and Cox regression were used to calculate the adjusted mean HAQ change and hazard ratios (HR). Results We identified 3,853 RA patients with diabetes and 18,487 without diabetes. The mean HAQ change between index and outcome visit among diabetes patients was 0.03 and non-diabetic was 0.002 (p<0.01). We identified 761 outpatient infections for diabetic patients with an IR of 22.6 (95% CI: 21.0-24.2) per 100 person years and 3,239 among non-diabetic patients with an IR of 19.8 (19.1-20.5). The adjusted HR of outpatient infection among diabetes was 0.99 (0.91-1.07), compared to non-diabetes patients. Conclusion RA patients with concomitant diabetes had greater worsening, or less improvement, in their functional status, suggesting additional interventions may be needed for RA patients with diabetes to optimize treatment and other comorbidities.

scholarly journals Prevalence of Depression and Associated Factors among Diabetic Patients in an Outpatient Diabetes Clinic

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Zahra D. Khan ◽  
Janet Lutale ◽  
Sibtain M. Moledina
Keyword(s):  
Associated Factors ◽  
Diabetic Patients ◽  
Mild Depression ◽  
Diabetes Clinic ◽  
Cross Sectional ◽  
Adequate Treatment ◽  
Moderate Depression ◽  
Prevalence Of Depression ◽  
Patients With Diabetes ◽  
Diabetes Patients

Despite adequate treatment for diabetes, it is estimated that 15%- 20% of people with diabetes are struggling with a moderate to severe form of depression daily. Little is known about depression in diabetes in East Africa, particularly in Tanzania. The study is aimed at determining the prevalence of depression and associated factors among patients with diabetes. A descriptive cross-sectional study was carried out at the diabetes clinic of Muhimbili National Hospital. The 9-item Patient Health Questionnaire (PHQ 9) scale was used to assess presence of depressive symptoms among diabetes patients at the clinic. In addition, patient’s sociodemographic and clinical characteristics were obtained and analysed for their association with depression. A total of 353 participants were recruited, of whom 229 (64.9%) patients were female and 156 (44.2%) were aged between 41 and 60 years. The overall prevalence of depression among diabetes patients at the diabetes clinic was 87%. Most (56.7%) had minimal depression, 22.1% had mild depression, and 8.2% had moderate depression. None had severe depression. Factors independently associated with a diagnosis of mild to moderate depression were being on insulin therapy and being a current smoker. There was a high prevalence of depression in this diabetic population. Majority of patients had minimal depression but about 30% had either mild or moderate depression. A holistic approach that focuses on the identification and management of depression among patients with diabetes is recommended.

scholarly journals Metformin decreases the risk of sudden sensorineural hearing loss in patients with diabetes mellitus: A 14-year follow-up study

2019 ◽  
Vol 16 (4) ◽  
pp. 324-327 ◽  
Author(s):  
Hsin-Chien Chen ◽  
Chi-Hsiang Chung ◽  
Chieh-Hua Lu ◽  
Wu-Chien Chien
Keyword(s):  
Diabetes Mellitus ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Cox Regression ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Lower Percentage ◽  
Research Database ◽  
Patients With Diabetes

Background: The risk of sudden sensorineural hearing loss associated with metformin use in patients with diabetes mellitus has not been fully examined. Study design: It is a retrospective matched-cohort study. Subjects and methods: We examined the medical records of patients with diabetes mellitus over 18 years old in Taiwan’s National Health Insurance Research Database for the period between 1 January 2000 and 31 December 2013, to establish matched cohorts (14,109 with and 42,327 without metformin use) at a ratio of 1:3 by sex, age and index year. Results: We used a Cox regression hazard model to identify risk factors of sudden sensorineural hearing loss during 14 years of follow-up, and the results indicate that a significantly lower percentage of diabetes mellitus patients with metformin use ( p = 0.033) developed sudden sensorineural hearing loss compared with those without metformin use (0.21%, 29/14,109 vs 0.32%, 136/42,327). After adjustment for age and other variables [adjusted hazard ratio: 0.630 (95% confidence interval: 0.422–0.941, p = 0.024)], this study also demonstrated that metformin use appeared to reduce the risk of developing sudden sensorineural hearing loss. Conclusion: This study demonstrated an association between metformin use and lower incidence of sudden sensorineural hearing loss among patients with diabetes mellitus.

scholarly journals Diagnostic Role of NT Pro BNP in Diabetes Type 2 Patients Associated with Cardiovascular Disease Risk, A Study from Central India

1970 ◽  
Vol 11 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Ashok Sahu ◽  
Trapti Gupta ◽  
Arvind Kavishwar ◽  
Purnima Dey Sarkar ◽  
RK Singh
Keyword(s):  
Cardiovascular Disease ◽  
Lipid Profile ◽  
Vascular Disease ◽  
Type Ii Diabetes ◽  
Type Ii ◽  
Patients With Diabetes ◽  
Cardio Vascular Disease ◽  
Cardio Vascular ◽  
Diabetes Patients

Cardiovascular disease is the most frequent cause of death in patient with diabetes. It is difficult to evaluate cardiovascular status of patients with diabetes because of complex symptomatology. NTproBNP, a split peptide from pro BNP molecule is a novel biomarker, released from cardiac myocytes in response to myocardial stretch, cardio vascular disease, endothelial dysfunction and heart failure. We aimed to test that is elevated NTproBNP levels associated with increased risk of cardiovascular disease in diabetes patients in comparison to matched control. Demographic, anthropometric measure, NT pro BNP, lipid profile, blood glucose were estimated and compared among angiographically proven cardiovascular disease patients with diabetes and healthy controls. Univariate and multivariate analysis were carried out to compare individual factor using t-Test, ANOVA and the inter group comparisons were done by using Bon ferroni Post Hoc test. Patients with type 2 diabetes were shown to have higher NTproBNP values (n=50, 1481.021±813.405) than control subjects (n=50, 23.562±23.395) (p <0.05). NTproBNP levels were independently related to diabetes after adjustment for age, sex, family history, smoking, obesity, blood pressure and lipid profile. Our data suggests that the secretion of NT pro BNP is increased in type II diabetes patients, suggesting association of diabetes and NTproBNP in cardio vascular disease with higher prevalence. Thus NTproBNP may serve as a screening tool to diagnose patients with type II diabetes with cardiovascular disease having complex symptomatology. Keyword: NTproBNP, Cardiovascular disease, Diabetes DOI:10.3329/jom.v11i1.4266 J Medicine 2010: 11: 33-38

Sign in / Sign up

Export Citation Format

Share Document